Cognition Therapeutics (CGTX) Competitors $3.18 +0.37 (+13.17%) Closing price 04:00 PM EasternExtended Trading$3.23 +0.05 (+1.48%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. CGEM, TNXP, ITOS, GOSS, RGNX, PRTA, TECX, EOLS, PRTC, and REPLShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), iTeos Therapeutics (ITOS), Gossamer Bio (GOSS), REGENXBIO (RGNX), Prothena (PRTA), Tectonic Therapeutic (TECX), Evolus (EOLS), PureTech Health (PRTC), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Its Competitors Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics Gossamer Bio REGENXBIO Prothena Tectonic Therapeutic Evolus PureTech Health Replimune Group Cullinan Therapeutics (NASDAQ:CGEM) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation. Which has more risk and volatility, CGEM or CGTX? Cullinan Therapeutics has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. Which has better valuation and earnings, CGEM or CGTX? Cognition Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$167.38M-$3.23-2.37Cognition TherapeuticsN/AN/A-$33.97M-$0.67-4.75 Do analysts rate CGEM or CGTX? Cullinan Therapeutics currently has a consensus price target of $26.80, indicating a potential upside of 250.79%. Cognition Therapeutics has a consensus price target of $2.83, indicating a potential downside of 10.90%. Given Cullinan Therapeutics' higher possible upside, research analysts clearly believe Cullinan Therapeutics is more favorable than Cognition Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Cognition Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer CGEM or CGTX? In the previous week, Cullinan Therapeutics had 17 more articles in the media than Cognition Therapeutics. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.95 beat Cullinan Therapeutics' score of 0.85 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals believe in CGEM or CGTX? 86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 6.1% of Cullinan Therapeutics shares are held by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is CGEM or CGTX more profitable? Cullinan Therapeutics' return on equity of -36.56% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -36.56% -34.82% Cognition Therapeutics N/A -251.23%-130.75% SummaryCullinan Therapeutics and Cognition Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$233.64M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-4.7520.9030.1925.84Price / SalesN/A386.36473.64122.75Price / CashN/A43.2325.7828.79Price / Book10.269.649.425.99Net Income-$33.97M-$54.08M$3.27B$265.29M7 Day Performance113.42%2.62%2.05%2.53%1 Month Performance278.57%4.05%3.58%0.93%1 Year Performance330.89%9.48%30.09%18.70% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics1.6268 of 5 stars$3.18+13.2%$2.83-10.9%+280.8%$233.64MN/A-4.7520Positive NewsGap UpHigh Trading VolumeCGEMCullinan Therapeutics1.9128 of 5 stars$7.95+3.8%$28.60+259.7%-54.6%$452.51MN/A-2.4630News CoverageAnalyst RevisionTNXPTonix Pharmaceuticals2.9848 of 5 stars$40.07-22.0%$70.00+74.7%+11.7%$450.13M$10.09M-1.0250High Trading VolumeITOSiTeos Therapeutics2.6874 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M-2.1690Positive NewsGOSSGossamer Bio3.2721 of 5 stars$1.99+1.5%$8.50+327.1%+157.5%$445.67M$114.70M-3.21180RGNXREGENXBIO4.3594 of 5 stars$8.71-1.2%$28.38+225.8%-25.7%$445.54M$83.33M-2.53370PRTAProthena3.5517 of 5 stars$8.53+3.4%$30.25+254.6%-59.6%$444.10M$135.16M-1.51130TECXTectonic Therapeutic2.1075 of 5 stars$24.71+5.1%$80.33+225.1%+43.8%$439.92MN/A-6.12120Positive NewsEOLSEvolus4.1855 of 5 stars$6.69-0.6%$21.25+217.6%-51.6%$435.33M$266.27M-6.83170News CoveragePRTCPureTech Health2.6267 of 5 stars$19.84+10.2%$45.00+126.8%-16.7%$434.61M$4.83M0.00100Upcoming EarningsGap UpREPLReplimune Group4.4294 of 5 stars$5.33-4.1%$7.67+43.8%-44.1%$433.99MN/A-1.65210Gap Down Related Companies and Tools Related Companies Cullinan Therapeutics Competitors Tonix Pharmaceuticals Competitors iTeos Therapeutics Competitors Gossamer Bio Competitors REGENXBIO Competitors Prothena Competitors Tectonic Therapeutic Competitors Evolus Competitors PureTech Health Competitors Replimune Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access